Armata Pharmaceuticals

Update in progress

ARMP (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies to address antibiotic‑resistant infections worldwide. Using its proprietary phage technology, it advances candidates such as AP‑SA02 for Staphylococcus aureus bacteremia and AP‑PA03 for Pseudomonas aeruginosa. Headquartered in Los Angeles, Armata operates as a subsidiary of Innoviva, Inc.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive